DEEP EXPERIENCE. SHARED COMMITMENT.
"We take a private equity approach to a sector that’s traditionally been dominated by venture and early-stage growth firms. We'll work very closely with management to improve the operations of the business, update the product portfolio and revamp the commercial organization. We provide the support and resources our portfolio companies need to succeed.”
21
active portfolio companies
+
2000
employees worldwide
7
AP-II Investments to Date
9
successful exits
news
Jun 18, 2025
Bioness Medical Announces Acquisition of the Assets and Business of Harmonic Bionics
Accelmed portfolio company Bioness Medical, Inc. announced the acquisition of the assets and business of Harmonic Bionics, a robotics company focused on improving neuro rehabilitation patient upper extremity mobility and function deficits.
This marks Bioness Medical's first acquisition since becoming an independent neuro rehabilitation company following its acquisition by Accelmed on December 31, 2024.
Jun 02, 2025
Acclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser TechnologyAcclaro Medical, a pioneering medical technology company focused on developing cutting-edge solutions that improve patient care and redefine medical practices, proudly announces the successful completion of its Series B funding round. Led by Accelmed Partners with participation by existing investor 3E Bioventures Capital, the combined funding of $23 million marks a pivotal milestone in the company's journey to fulfill unmet aesthetic needs through its innovative 2910 nm fiber laser solution and other disruptive technologies.
Apr 15, 2025
Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United StatesAccelmed portfolio company Click Therapeutics, Inc., (“Click”) a leader in prescription medical treatments as both prescription digital therapeutics and software-enhanced drug™ therapies, has obtained FDA marketing authorization for the first prescription digital therapeutic for the preventive treatment of episodic migraine
Mar 28, 2025
Keystone Dental Appoints Tony Susino as Chief Executive Officer & Board MemberKeystone Dental Holdings, Inc. announced the appointment of Tony Susino as Chief Executive Officer and member of its Board of Directors, effective immediately
Contact Us